Daratumumab & Lenalidomide Maintenance Therapy Significantly Improves Outcomes in newly Diagnosed Multiple Myeloma
Recent data from the phase 3 AURIGA study demonstrate a compelling benefit to adding daratumumab subcutaneous (Dara-SC) to lenalidomide maintenance therapy for patients with newly diagnosed multiple myeloma (NDMM) who achieve minimal residual disease (MRD) positivity following autologous stem cell transplant (ASCT). This combination not only deepens MRD negativity but also significantly extends progression-free survival (PFS) with a manageable safety profile.
Understanding the AURIGA Study & Patient Population
The AURIGA trial enrolled patients who had not previously received CD38-directed therapy as part of their initial treatment regimen. Participants were required to have achieved at least a Very Good partial Response (VGPR) prior to enrollment and demonstrated MRD positivity at a threshold of 10-6. Patients were randomized 1:1 to recieve either Dara-SC plus lenalidomide (DR) or lenalidomide alone (R), with stratification based on high-risk cytogenetics. The study population was largely comprised of patients who had undergone intensive induction therapy – a median of five cycles, with over 80% receiving bortezomib and lenalidomide, and 70% achieving VGPR at baseline.
key Findings: Deepening MRD Negativity & Prolonged Progression-Free Survival
The primary endpoint of the study – 12-month MRD negative conversion rate – previously showed a more than doubling of response rates with the Dara-SC/lenalidomide combination. The 24-month update reinforces these findings, demonstrating sustained improvements across all patient subgroups, nonetheless of age, stage, race, or cytogenetic risk.
Specifically, the AURIGA study revealed:
* Enhanced MRD Negativity: Daratumumab/lenalidomide significantly increased MRD negative conversion rates, more than doubling sustained negativity at the 6-month mark (10-6 threshold) and nearly quadrupling it at 12 months.
* Extended progression-Free Survival: with a median follow-up of 40.3 months, the hazard ratio for progression or death favored the Dara-SC/lenalidomide arm (HR 0.55), representing a 45% reduction in risk. Median PFS has not yet been reached in the DR cohort, compared to 47 months in the R cohort. At 36 months, PFS rates were 78.6% for DR versus 61.4% for R.
* Improved Treatment Duration: Patients receiving Dara-SC/lenalidomide remained on treatment for a longer duration, with a higher proportion completing at least 24 cycles compared to those on lenalidomide alone.
* Favorable Safety Profile: Importantly,the addition of Dara-SC did not increase the incidence of grade 3 or 4 adverse events,nor did it lead to a higher rate of treatment discontinuation. Actually, discontinuation rates were lower in the DR arm.
* Trend Towards Improved Overall Survival: While overall survival data remains immature, a trend towards increased survival was observed with the Dara-SC/lenalidomide combination.
Pharmacist’s Role: Monitoring for Adverse Events & Optimizing Patient Management
Pharmacists play a crucial role in the safe and effective management of patients receiving dara-SC/lenalidomide maintenance therapy. Given the potential for adverse events associated with daratumumab, notably with the initial doses, vigilance is paramount.
Key Adverse Events to Monitor:
* Infusion/Injection Reactions: These are most common with the first dose of daratumumab. Pharmacists should ensure appropriate pre-medication protocols are followed and that patients are closely monitored during and after infusion for symptoms like fever, chills, cough, and dyspnea.
* Hematologic toxicities: Regular blood count monitoring is essential to identify and manage neutropenia, thrombocytopenia, and anemia. Dose adjustments or growth factor support may be necessary.
* Infections: Anti-CD38 therapies can increase the risk of infections. Pharmacists should counsel patients on recognizing signs and symptoms of infection and emphasize the importance of prompt medical attention.Prophylactic measures, such as antiviral and antibacterial prophylaxis, may be considered based on individual risk factors.
* Lenalidomide-Related Toxicities: Pharmacists must also be aware of the potential adverse effects of lenalidomide, including myelosuppression, venous thromboembolism (VTE), and teratogenicity. Appropriate risk mitigation strategies, including VTE prophylaxis and strict adherence to REMS requirements for lenalidom
Related reading